Insense Overview

  • Founded
  • 2000

Founded

  • Status
  • Private

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $323K

  • Investors
  • 3

Insense General Information

Description

Operator of a biotechnology company intended to offer advanced medical and personal care products. The company offers products that help in the treatment of skin and nail conditions and also offers a cure for skin wrinkles neuropathic pain, acne, and active transdermal patches, enabling client dermatology products for both professional and consumer applications to maintain skin at an affordable price.

Contact Information

Website
www.insense.co.uk
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Personal Products
Primary Office
  • Colworth Science Park
  • Sharnbrook
  • Bedfordshire MK44 1LQ
  • England, United Kingdom
+44 07889 000000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Insense Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Later Stage VC 08-Apr-2011 $323K 00.00 Completed Generating Revenue
2. Early Stage VC 20-Oct-2003 00.000 00.000 Completed Generating Revenue
1. Early Stage VC 01-Jun-2001 $291K $291K Completed Startup
To view Insense’s complete valuation and funding history, request access »

Insense Patents

  • 111

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 7

    Granted

  • 3

    Pending

  • 000

    Expiring in next 12 mo

Insense Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-201915768-D0 Treatment of lung conditions Inactive 30-Oct-2019
CA-3152119-A1 Composition for delivering nitric oxide to skin Pending 07-Oct-2019 00000000
CA-3152127-A1 Composition for delivering nitric oxide to skin Pending 07-Oct-2019 00000000
EP-3986359-A1 Composition for delivering nitric oxide to skin Pending 07-Oct-2019 00000000
EP-3986376-A1 Composition for delivering nitric oxide to skin Pending 07-Oct-2019 A61K8/19
To view Insense’s complete patent history, request access »

Insense Executive Team (2)

Name Title Board Seat Contact Info
Christopher Hunt Chief Executive Officer & Board Member
Paul Davis Founder, Chief Scientific Officer & Board Member
To view Insense’s complete executive team members history, request access »

Insense Board Members (4)

Name Representing Role Since
Christopher Hunt Insense Chief Executive Officer & Board Member 000 0000
Paul Davis Insense Founder, Chief Scientific Officer & Board Member 000 0000
Stewart Newton Self Board Member 000 0000
You’re viewing 3 of 4 board members. Get the full list »

Insense Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Seneca Growth Capital VCT Venture Capital Minority 000 0000 000000 0
Unilever Ventures Corporate Venture Capital Minority 000 0000 000000 0
Oxford Technology Management Venture Capital Minority 000 0000 000000 0
To view Insense’s complete investors history, request access »

Ready to get started?

Request a free trial